Extended contract now covers a total of 11 European countries Crossject will receive milestone payments of up to ‚1 million in total, upon marketing authorizations Crossject will sell ZEPIZURE®...
Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary...
Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDAExpectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE®...
Dijon, France April 2, 2024 “ Trading of the stock of Crossject (ISIN: FR0011716265; Euronext: ALCJ) on the Euronext exchange will resume as normal on Wednesday, April 3 at 09:00 CET. Crossject's...
Crossject gender equality score reaches 96/100 in 2024
Dijon, February 27, 2024 at 8:30am Crossject obtains a financing up to ‚¬12 million, in two tranches,from an entity managed by Heights Capital Management, in issued bondsconvertible in new shares,...
Focusing on regulatory filings and accelerating U.S. commercialization efforts Contract of up to $155 million with BARDA for U.S. stockpiling continues to advance Dijon, France February 6, 2024 “530...
Dijon, France, February 1, 2024 -- 18:15 CET - Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, will hold a...
Press Release Crossject to present at Biotech Showcase on January 9 at 16:30 PT Dijon, France, January 9, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company...
Press Release Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE® ï€ Crossject expanding market access activities in preparation for filing for marketing authorization ...